Featured News

4 Sep 2025

Exclusive: Biotech’s Latest Unicorn Uses AI to Mine Nature’s Medicine Chest

Nature is a prolific pharmacist. Aspirin, the blood thinner warfarin and metformin for diabetes all trace back to plants, discovered by serendipity before being transformed into drugs by modern chemistry.

24 Mar 2026

Enveda named one of the Most Innovative Companies in biotech by Fast Company

10 Sep 2025

Enveda Raises $150 Million To Use AI To Develop Drugs From Nature

5 Sep 2025

Enveda Gets New Backing to Scour Nature for Promising Compounds

4 Sep 2025

Enveda CEO Reveals How It Will Deploy $150M in Series D Funding

4 Sep 2025

Enveda raises $150M for drug development, reaching unicorn status

4 Sep 2025

Enveda collects another $150M for I&I drug, sprawling pipeline of preclinical assets

24 Jun 2025

Enveda: Cracking the chemical code of life with AI

25 Mar 2025

America’s Greatest Startup Workplaces 2025

4 Mar 2025

2025 America’s Best Startup Employers

21 Nov 2024

AI Drug Discovery Startup Enveda Raises $130 Million

14 Jun 2024

Enveda raises $55M to combine ancient remedies with AI for drug discovery

30 May 2024

Enveda translates life’s chemistry into medicines

14 Feb 2023

TRANSFORMing natural product drug discovery: machine learning for high-fidelity chemical property prediction from metabolomics data

Press Releases

15 Apr 2026

Enveda Appoints Christopher K. Porter, MBA, JD as Senior Vice President, Clinical Operations

31 Mar 2026

Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial of Patients with Moderate-to-Severe Atopic Dermatitis

23 Dec 2025

Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease

17 Dec 2025

Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead…

9 Dec 2025

Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma

28 May 2025

Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis

26 Feb 2025

Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M

5 Feb 2025

Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board

10 Jan 2025

Enveda Welcomes Jason Kim as Chief Financial Officer

21 Nov 2024

Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates

13 Nov 2024

Enveda Announces First Candidate Discovered From Nature Using AI Advances to Clinical Trials

1 Aug 2024

Enveda Biosciences Hires Chief Medical Officer to Advance Its Rich Pipeline of Therapeutic Programs into the Clinic

4 Sep 2025

Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors

14 Jun 2024

Enveda Biosciences Announces $55M in New Funding to Accelerate Platform and Advance Multiple Candidates to Clinical Trials

29 May 2024

Enveda Biosciences Announces Microsoft Collaboration and Reveals Foundation Model to “Read and Translate” Chemistry

21 Jun 2023

Enveda Biosciences unveils new AI algorithm to unlock nature’s chemical code

20 Apr 2023

Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million

21 Dec 2022

Enveda Biosciences Closes $68-million Combined Series B Equity and Debt Financing

22 Jun 2021

Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital

Site by Maven Creative

Featured News

Exclusive: Biotech’s Latest Unicorn Uses AI to Mine Nature’s Medicine Chest

Enveda named one of the Most Innovative Companies in biotech by Fast Company

Enveda Raises $150 Million To Use AI To Develop Drugs From Nature

Enveda Gets New Backing to Scour Nature for Promising Compounds

Enveda CEO Reveals How It Will Deploy $150M in Series D Funding

Enveda raises $150M for drug development, reaching unicorn status

Enveda collects another $150M for I&I drug, sprawling pipeline of preclinical assets

Enveda: Cracking the chemical code of life with AI

America’s Greatest Startup Workplaces 2025

2025 America’s Best Startup Employers

AI Drug Discovery Startup Enveda Raises $130 Million

Enveda raises $55M to combine ancient remedies with AI for drug discovery

Enveda translates life’s chemistry into medicines

TRANSFORMing natural product drug discovery: machine learning for high-fidelity chemical property prediction from metabolomics data

WHAT’S GOING ON AT ENVEDA

Press Releases

Enveda Appoints Christopher K. Porter, MBA, JD as Senior Vice President, Clinical Operations

Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial of Patients with Moderate-to-Severe Atopic Dermatitis

Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory Bowel Disease

Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308, a First-in-Class Oral Therapy for Obesity; Appoints Nadeem Sarwar, Ph.D., MPharm, MPhil, to Lead…

Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma

Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis

Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M

Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board

Enveda Welcomes Jason Kim as Chief Financial Officer

Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates

Enveda Announces First Candidate Discovered From Nature Using AI Advances to Clinical Trials

Enveda Biosciences Hires Chief Medical Officer to Advance Its Rich Pipeline of Therapeutic Programs into the Clinic

Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors

Enveda Biosciences Announces $55M in New Funding to Accelerate Platform and Advance Multiple Candidates to Clinical Trials

Enveda Biosciences Announces Microsoft Collaboration and Reveals Foundation Model to “Read and Translate” Chemistry

Enveda Biosciences unveils new AI algorithm to unlock nature’s chemical code

Enveda Biosciences Announces Oversubscribed Series B1 Bringing Total Round to US$119 Million

Enveda Biosciences Closes $68-million Combined Series B Equity and Debt Financing

Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital